1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Can Fresh INTEREST Breathe New Life Into Faron's Traumakine?

 
• By Kevin Grogan

Faron's ARDS drug looked doomed after the INTEREST study earlier this year but the Finnish group claims that a DNA analysis has identified some patients for whom Traumakine treatment could potentially be effective.

Diver
Faron dives deep for positive data • Source: Shutterstock

Faron Pharmaceuticals Oy has seen its stock jump after the Finland-headquartered group identified a subgroup of respiratory distress syndrome (ARDS) patients from a failed late-stage trial who may benefit from Traumakine (interferon-beta 1a).

The firm's prospects for Tramakine looked extremely bleak in May when Faron reported top-line data showing that the drug failed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

PureTech Ponders Way Forward As CEO Exits

 
• By Kevin Grogan

Bharatt Chowrira departs days after firm’s chair stepped down.